1例产超广谱β—内酰胺酶肺炎克雷伯菌重症肺炎患者的药学监护(4)
[11] 郭春钰,严金玲,黄子倩,等.临床药师参与1例重症肺炎抗感染治疗的病例分析[J].中国医院药学杂志,2013,33(1):72-74.
[12] 盛长城,钱鑫,陈琦.临床药师参与1例重症医院获得性肺炎患者的治疗实践与体会[J].中国药师,2016,19(1):137-139.
[13] MONTERO JG,PIZARRAYA AG,ORTEGA AE,et al.De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock[J]. Intensive Care Med,2014,40(1):32-40.
[14] 刘慧招.亚胺培南/西司他丁对重症肺炎的降阶梯治疗疗效分析[J].中外医疗,2016,14(5):162-164.
[15] CHRISTIAN WT,BETTINA RE,ULRIKE PN,et al. Immune mediators in patients with acute diabetic foot syndrome[J]. Diabetes Care,2009,32(8):1491-1496.
[16] 贺毅,陆坚.治疗产ESBLs细菌感染的研究进展[J].國外医药抗生素分册,2012,33(4):145-150.
[17] 周华,周建英,俞云松.多重耐药革兰阴性杆菌感染诊治专家共识[J].中华内科杂志,2014,53(12):984-986.
[18] 赵莹,李娟,黄蓓晖,等.哌拉西林-他唑巴坦在恶性血液病粒细胞缺乏伴发热经验性治疗中的应用[J].中国感染与化疗杂志,2008,8(3):200-203.
[19] 霍永生,章辉,王伟华,等.美罗培南与哌拉西林舒巴坦在治疗慢性阻塞性肺病急性发作中的临床对比分析[J].中国实用医药,2012,7(36):6-8.
[20] AZEEM E,HAMDY G,SARAYA M,et al. The role of procalcitonin as a guide for the diagnosis,prognosis,and decison of antibiotic therapy for lower respiratory tract infections[J]. Egyptian Journal of Chest Diseases and Tuberculosis,2013,62:687-695.
[21] 顾鹏,周世文.以降钙素原指导脓毒症患者抗菌药物应用的Meta分析[J].中国药房,2017,28(6):791-794.
[22] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识[J].中华急诊医学杂志,2012,21(9):944-948.
[23] 王芊,华川.不同细菌感染患者血清降钙素原、C反应蛋白和WBC水平差异的研究[J].国际检验医学杂志,2014,35(17):2301-2302.
[24] JONES AE,FIECHTL JF,BROWN MD,et al. Procalcitonin test in the diagnosis of bacteremia:a meta-analysis[J].Ann Emerg Med,2007,50(1):34-41.
[25] DRUSANO GL. Antimicrobial pharmacodynamics:critical interactions of“bug and drug”[J]. Microbiology,2004,2(4):289-290.
[26] 杨燕,高尚兰,刘国伟.亚胺培南西司他丁长时程给药对重症肺炎患者康复进程的影响[J].中国医学工程,2016,24(11):22-24.
[27] ELSEVIERS M,VAN CY,NAYAERT S,et al. Prevalence and management of antibiotic associated diarrhea in general hospitals[J]. Infectious Diseases,2015,15(129):1-9.
(收稿日期:2017-10-09 修回日期:2017-11-21)
(编辑:刘明伟), http://www.100md.com(孙琼华 吕亚青 郑文灿)
[12] 盛长城,钱鑫,陈琦.临床药师参与1例重症医院获得性肺炎患者的治疗实践与体会[J].中国药师,2016,19(1):137-139.
[13] MONTERO JG,PIZARRAYA AG,ORTEGA AE,et al.De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock[J]. Intensive Care Med,2014,40(1):32-40.
[14] 刘慧招.亚胺培南/西司他丁对重症肺炎的降阶梯治疗疗效分析[J].中外医疗,2016,14(5):162-164.
[15] CHRISTIAN WT,BETTINA RE,ULRIKE PN,et al. Immune mediators in patients with acute diabetic foot syndrome[J]. Diabetes Care,2009,32(8):1491-1496.
[16] 贺毅,陆坚.治疗产ESBLs细菌感染的研究进展[J].國外医药抗生素分册,2012,33(4):145-150.
[17] 周华,周建英,俞云松.多重耐药革兰阴性杆菌感染诊治专家共识[J].中华内科杂志,2014,53(12):984-986.
[18] 赵莹,李娟,黄蓓晖,等.哌拉西林-他唑巴坦在恶性血液病粒细胞缺乏伴发热经验性治疗中的应用[J].中国感染与化疗杂志,2008,8(3):200-203.
[19] 霍永生,章辉,王伟华,等.美罗培南与哌拉西林舒巴坦在治疗慢性阻塞性肺病急性发作中的临床对比分析[J].中国实用医药,2012,7(36):6-8.
[20] AZEEM E,HAMDY G,SARAYA M,et al. The role of procalcitonin as a guide for the diagnosis,prognosis,and decison of antibiotic therapy for lower respiratory tract infections[J]. Egyptian Journal of Chest Diseases and Tuberculosis,2013,62:687-695.
[21] 顾鹏,周世文.以降钙素原指导脓毒症患者抗菌药物应用的Meta分析[J].中国药房,2017,28(6):791-794.
[22] 降钙素原急诊临床应用专家共识组.降钙素原(PCT)急诊临床应用的专家共识[J].中华急诊医学杂志,2012,21(9):944-948.
[23] 王芊,华川.不同细菌感染患者血清降钙素原、C反应蛋白和WBC水平差异的研究[J].国际检验医学杂志,2014,35(17):2301-2302.
[24] JONES AE,FIECHTL JF,BROWN MD,et al. Procalcitonin test in the diagnosis of bacteremia:a meta-analysis[J].Ann Emerg Med,2007,50(1):34-41.
[25] DRUSANO GL. Antimicrobial pharmacodynamics:critical interactions of“bug and drug”[J]. Microbiology,2004,2(4):289-290.
[26] 杨燕,高尚兰,刘国伟.亚胺培南西司他丁长时程给药对重症肺炎患者康复进程的影响[J].中国医学工程,2016,24(11):22-24.
[27] ELSEVIERS M,VAN CY,NAYAERT S,et al. Prevalence and management of antibiotic associated diarrhea in general hospitals[J]. Infectious Diseases,2015,15(129):1-9.
(收稿日期:2017-10-09 修回日期:2017-11-21)
(编辑:刘明伟), http://www.100md.com(孙琼华 吕亚青 郑文灿)